|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder | |||
| 化学式 | C25H19N5S |
||||||
| 分子量 | 421.52 | CAS No. | 909910-43-6 | ||||
| Solubility (25°C)* | 体外 | DMSO | 21 mg/mL (49.81 mM) | ||||
| Water | Insoluble | ||||||
| Ethanol | Insoluble | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | A-83-01 is a potent inhibitor of TGF-β type I receptor (ALK5-TD) with IC50 of 12 nM. A-83-01 also inhibits the transcription induced by activin/nodal type I receptor (ALK4-TD) and nodal type I receptor (ALK7-TD) with IC50 of 45 nM and 7.5 nM, respectively.Solutions are unstable and should be fresh-prepared. |
|---|---|
| in vitro | A-83-01 inhibits the transcriptional activity induced by TGF-β type I receptor ALK-5 and that by activin type IB receptor ALK-4 and nodal type I receptor ALK-7, the kinase domains of which are structurally highly related to those of ALK-5. This compound is potent in the inhibition of ALK5 and also prevents phosphorylation of Smad2/3 and the growth inhibition induced by TGF-β.[1] |
| in vivo | A83-01 treatment significantly increases the number of Nkx2.5+ cardiomyoblasts at baseline and after myocardial injury, resulting in an increase in newly formed cardiomyocytes. This compound significantly improves ventricular elastance and stroke work, leading to improved contractility after injury.[2] |
| 細胞アッセイ | 細胞株 | Wild-type mink lung epithelial (Mv1Lu) cells, R mutant of Mv1Lu (R4-2) cells, HaCaT cells, C2C12 cells, NMuMG cells |
|---|---|---|
| 濃度 | 1 μM | |
| 反応時間 | 1 h | |
| 実験の流れ | Cell proliferation assay: Mv1Lu cells are seeded in duplicate at a density of 2.5 × 104 cells/well in 24-well plates. The following day, cells are pretreated for 1 h with 1 μM A-83-01 and then cultured with TGF-β (1 ng/mL) for 24 h, 48 h, or 72 h. Cells are trypsinized and counted with a Coulter counter. To explore whether this compound reduces the growth-inhibitory effects of TGF-β in concentration-dependent fashion, Mv1Lu cells are seeded as above and pretreated for 1 h with various concentrations of this chemical. After pretreatment, cells are cultured with TGF-β (1 ng/mL) for 48 h and counted. |
|
| 動物実験 | 動物モデル | 8–10 week old Nkx2.5 enhancer-eGFP transgenic mice |
| 投薬量 | 10 mg/kg | |
| 投与方法 | IP |
|
| A complete model of mouse embryogenesis through organogenesis enabled by chemically induced embryo founder cells [ Cell, 2025, S0092-8674(25)00807-4] | PubMed: 40780195 |
| Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters [ Nat Genet, 2025, 57(1):165-179] | PubMed: 39806204 |
| Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters [ Nat Genet, 2025, 57(1):165-179] | PubMed: 39806204 |
| Bat organoids reveal antiviral responses at epithelial surfaces [ Nat Immunol, 2025, 10.1038/s41590-025-02155-1] | PubMed: 40399606 |
| Matrix directs trophoblast differentiation in a bioprinted organoid model of early placental development [ Nat Commun, 2025, 16(1):8267] | PubMed: 40940337 |
| Control of Golgi- V-ATPase through Sac1-dependent co-regulation of PI(4)P and cholesterol [ Nat Commun, 2025, 16(1):7808] | PubMed: 40841558 |
| Microbial metabolites control self-renewal and precancerous progression of human cervical stem cells [ Nat Commun, 2025, 16(1):2327] | PubMed: 40057497 |
| RSAD2: A pathogenic interferon-stimulated gene at the maternal-fetal interface of patients with systemic lupus erythematosus [ Cell Rep Med, 2025, S2666-3791(25)00047-3] | PubMed: 39983716 |
| A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival [ Biomaterials, 2025, 314:122838] | PubMed: 39348736 |
| Blocking CXCR4+ CD4+ T cells reprograms Treg-mediated immunosuppression via modulating the Rho-GTPase/NF-κB signaling axis [ Genome Med, 2025, 17(1):85] | PubMed: 40760450 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。